Tools for Practice Outils pour la pratique

#23 Ezetimibe: Lowers LDL cholesterol but what else?

Does Ezetimibe (Ezetrol) modify clinical outcomes?

Only the IMPROVE-IT trial provides meaningful data on ezetimibe. In acute coronary syndrome patients, adding ezetimibe to moderate-intensity statin prevents one cardiovascular event for every 50 people treated for seven years. Baseline LDL level did not influence this benefit. There are no data for ezetimibe in primary prevention, but the benefit is likely proportional to (lower) baseline CVD risk.

CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session

Randomized controlled trials (RCTs) of ezetimibe 10 mg or placebo added to statin:
  • IMPROVE-IT:1-3 18,144 patients with acute coronary syndrome (within 10 days) and LDL 1.3-3.2 mmol/L.
    • Ezetimibe lowered LDL by 0.43 mmol/L (24%) at one year.
    • Clinical outcomes at seven years:
      • Mortality: No difference (15.4% vs 15.3%).
      • Significantly reduced cardiovascular disease (CVD): 32.7% vs 34.7%, number needed to treat (NNT)=50.
      • Significantly reduced myocardial infarction (NNT=59) and ischemic stroke (NNT=167).
      • Note: Benefit seen regardless of baseline LDL level.
      • No difference in adverse events, including cancer, gastrointestinal, and musculoskeletal.
  • ENHANCE: 4 720 patients with familial hypercholesterolemia. No difference in events at two years.
    • 262 vascular surgery patients: 5 No difference in events at one year.
  • RCT of 363 patients comparing ezetimibe versus niacin (only other active comparator trial): 6
    • Significantly increased CVD events with ezetimibe (5% vs 1%) at 14 months.

  • Two RCTs of statin plus ezetimibe versus placebo in which effect of ezetimibe and statin cannot be separated:
    • SEAS: 7 1,873 aortic stenosis patients: No difference in composite valvular/ischemic CVD events.
    • SHARP: 8 9,270 chronic kidney disease patients (⅓ on dialysis): Significantly reduced CVD 11.3% vs 13.4% (NNT=48).
  • No primary prevention data for ezetimibe. If the relative effects are generalizable (as they are for statins9 ), for patients receiving low-moderate intensity statin (e.g. simvastatin 20-40 mg or atorvastatin 10 mg):
    • Adding ezetimibe would prevent one CVD event in:
      • ~100 high-risk patients (20% baseline 10-year CVD risk).
      • ~200 low-risk patients (10% baseline 10-year CVD risk).1-3
    • Whereas increasing to high-intensity statin (e.g. atorvastatin 80 mg) would prevent one CVD event in:
      • ~43 high-risk patients.
      • ~85 low-risk patients. 9

Latest Tools for Practice
Derniers outils pour la pratique

#370 Antibiotics or no antibiotics for acute diverticulitis, that is the question!

Do antibiotics change clinical outcomes for patients with acute uncomplicated diverticulitis?
Read Lire 0.25 credits available Crédits disponibles

#369 Remind me, do medications that target brain amyloid improve my dementia?

Are amyloid-targeting monoclonal antibodies safe and effective for mild cognitive impairment or Alzheimer’s dementia?
Read Lire 0.25 credits available Crédits disponibles

#368 Sodium Restriction in Heart Failure: Beneficial or pouring salt in the wound?

Does sodium restriction improve outcomes in patients with chronic heart failure?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session

  • G. Michael Allan MD CCFP
  • Kelly B Zarnke MD MSc FRCP (General Internal Medicine)

1. Cannon CP, Giugliano RP, Blazing MA, et al. Am Heart J. 2008; 156:826-32.

2. IMPROVE-IT slides from American Heart Association (AHA) 2014 Scientific Sessions (accessed 2014 Dec 16):

3. IMPROVE-IT: ‘Modest’ benefit when adding ezetimibe to statins in post-ACS patients (accessed 2014 Dec 16). Available from:

4. Kastelein JJ, Akdim F, Stroes ES, et al. N Engl J Med. 2008; 358:1431-43.

5. Kouvelos GN, Arnaoutoglou EM, Matsagkas MI, et al. J Cardiovasc Pharmacol Ther. 2013; 18:5-12.

6. Taylor AJ, Villies TC, Stanek EJ, et al. N Engl J Med. 2009;361:2113-22.

7. Rossebø AB, Pedersen TR, Boman K, et al. N Engl J Med. 2008; 359:1343-56

8. Baigent C, Landray MJ, Reith C, et al. Lancet. 2011; 377(9784):2181-92.

9. Cholesterol Treatment Trialists’ (CTT) Collaboration. Lancet. 2010; 376:1670-81.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.